Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 25, 2024
Daily News
March 25, 2024
- Japan’s 1st Eylea Biosimilar Approval on Horizon? JAN Now Decided
March 25, 2024
- Daiichi Sankyo Eyes 7 Additional Indications for Enhertu by 2026
March 25, 2024
- Ono Hooks Up with Oxford on Drug Discovery Research
March 25, 2024
- EMA Delays Decision on Leqembi Due to Procedural Issues
March 25, 2024
- Iclusig Gets Additional FDA Nod for Iclusig in Ph+ ALL: Takeda
March 25, 2024
- Novartis, Sandoz Recall Entacapone Products over Carcinogenic Risk
March 25, 2024
- Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
- Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
March 25, 2024
- Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…